Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2017

View Archived Issues

Preclinical characterization of a novel selective PI3Kalpha inhibitor, GDC-0077

LY-3214996 demonstrates potent antitumor activity in cancer models with MAPK pathway alterations

Discovery and preclinical characterization of novel JAK1 inhibitor AZD-4205

FDA approves Gilead Sciences' Harvoni and Sovaldi in pediatric patients

First data from first-in-human study of FGFR-4 inhibitor FGF-401 reported

Janssen identifies novel FGFR inhibitors

NSTDA patents dihydrofolate reductase inhibitors

Merck KGaA discloses new IRAK-1/4 inhibitors

IASOtoc now available in France, Austria and Germany

Phase II PREVACEbola vaccine study launched in West Africa to evaluate three vaccination strategies

Akorn and Fresenius Kabi in discussions regarding potential acquisition

PeptiDream and Janssen enter discovery and collaboration agreement

Kyowa Hakko Kirin announces positive results from the phase III MAVORIC clinical trial

Themis Bioscience initiates phase I dose-finding study of MV-ZIKA vaccine

Kura Oncology begins phase I study of KO-947 in nonhematological malignancies

Sunshine Lake Pharma, Calitor Sciences patent JAK, FLT-3 and Aurora kinase inhibitors

Medivir announces completion of phase II remetinostat study in CTCL

Assembly Biosciences, IURTC present HBV core protein modulators

Fred Hutch announces faculty and staff achievements

FDA issues complete response letter regarding Merck & Co.'s sitagliption sNDAs

Celgene describes in vivo antitumor activity of anti-CD47 monoclonal antibody CC-90002

Cipla and MEDRx enter into a collaboration for MRX-4TZT

Nanotherapeutics begins enrollment in phase I trial of NTM-1634

Indian FDA approves first autologous dendritic cell-based immuno-oncology product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...